Trial Profile

A single-arm, open-label, multi-cohort phase II clinical trial evaluating the efficacy and safety of orelabrutinib in combination with tafasitamab + lenalidomide for the treatment of patients with relapsed or refractory Non-Hodgkin's lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Orelabrutinib (Primary) ; Tafasitamab (Primary)
Indications Non-Hodgkin's lymphoma
Focus Therapeutic Use

18 Apr 2023 According to InnoCare media release, data from this study presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
18 Apr 2023 Status changed from not yet recruiting to recruiting as per InnoCare media release
18 Apr 2023 Results published in the InnoCare Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com